pembrolizumab,lenvatinib
merck,eisai
['hcc', 'leap-002', 'lenva']
keep up with all the latest data from #esmo22 - in today's news: non-statistically significant os and pfs findings from the leap-002 phase iii trial support lenvatinib monotherapy as soc in advanced hepatocellular carcinoma (ahcc). stay tuned for more #noeticinsight updates... 